Study guide
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C)
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C)
Key Takeaways Explain This Topic AI
Essential documents are defined under ICH E6(R3) Appendix C.1 as those documents that individually and collectively permit evaluation of the conduct of a trial and the quality of data produced.
Pre-trial documentation establishes regulatory authorization, ethical approval, investigator qualifications, baseline laboratory standards, and the safety/scientific rationale before any participant is enrolled.
During-trial documentation captures dynamic trial events including protocol amendments, continuing IRB approvals, safety notifications (SUSARs/IND Safety Reports), IP accountability, and monitoring visit reports.
Post-trial documentation accounts for final investigational product reconciliation and destruction, unblinding documentation, subject identification code archiving, close-out reports, and clinical study reports.
The Subject Identification Code List and original signed informed consent forms must remain strictly under the investigator's custody at the site and must never be transferred to the sponsor TMF.
Last updated: August 2026
2.1 Essential Documents Before, During, and After Trial (ICH E6(R3) Appendix C)
Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Appendix C, Essential Records for the Conduct of a Clinical Trial — note the rename from "essential documents", which makes the requirement media-neutral.
ACRP-CP Exam Focus: Essential documents serve two primary functions: they demonstrate the compliance of the investigator, sponsor, and monitor with Good Clinical Practice (GCP) standards and applicable regulatory requirements, and they allow for the independent evaluation and reconstruction of trial conduct and data integrity. On the exam, expect scenario-based questions asking where specific documents belong (Sponsor TMF vs. Investigator Site File), what triggers mandatory updates (e.g., protocol amendments, new sub-investigators), and who holds legal custody of participant-identifying records.
1. Regulatory Foundation & Purpose of Essential Documents
Under ICH GCP E6(R3) Appendix C.1 , essential documents are defined as: Essential Documents = Records that individually and collectively permit evaluation of trial conduct and data quality \text{Essential Documents} = \text{Records that individually and collectively permit evaluation of trial conduct and data quality} Essential Documents = Records that individually and collectively permit evaluation of trial conduct and data quality
These documents provide the audit trail that enables both independent auditors (representing the sponsor) and regulatory inspectors (such as FDA BIMO, EMA, or MHRA) to verify that:
The rights, safety, and well-being of trial subjects were protected.
The trial was conducted in accordance with the approved protocol, ICH GCP, and applicable statutory regulations.
The data generated are authentic, complete, verifiable, and scientifically robust.
Filing essential documents in a timely and organized manner across the Investigator Site File (ISF) and the Sponsor Trial Master File (TMF) is a fundamental operational responsibility. An incomplete or poorly maintained document repository is one of the most frequent root causes of regulatory inspection findings, Form FDA 483 observations, and trial delays.
2. Stage 1: Before the Clinical Phase Begins (Pre-Trial Documents)
Before a trial can initiate screening or enroll its first subject, a comprehensive set of foundational documents must be established, approved, and filed. ICH E6(R3) Appendix C.2 specifies the pre-trial documents required to confirm that the site is qualified, the protocol is ethically and scientifically vetted, and proper regulatory clearances have been granted.
Comprehensive Breakdown of Pre-Trial Essential Documents
Document Name Primary Purpose Required Location
Investigator's Brochure (IB) Compiles preclinical and clinical data on the investigational product (IP) to provide scientific rationale and justify dose, route, safety monitoring, and risk management. Sponsor TMF & ISF
Signed Protocol & Protocol Amendments Documents agreement between sponsor and PI to conduct the trial in strict compliance with the protocol methodology. Sponsor TMF & ISF
Information Given to Subjects (ICF, Assent, Advertisements) Written documentation that subjects are fully informed of trial purpose, risks, benefits, procedures, and rights prior to participation. Sponsor TMF & ISF
Dated, Documented IRB/IEC Approval / Favorable Opinion Confirms that an independent ethics committee reviewed and approved the protocol, ICF, subject recruitment materials, and subject compensation. Sponsor TMF & ISF
IRB/IEC Composition / Roster / FWA Documents that the IRB/IEC is constituted in accordance with GCP/regulatory rules (e.g., proper mix of scientific/non-scientific, unaffiliated members). Sponsor TMF & ISF
Regulatory Authority (RA) Approvals / Notifications Demonstrates legal authorization to conduct the investigation in the jurisdiction (e.g., FDA IND authorization letter, EU Clinical Trial Authorization). Sponsor TMF & ISF (where required)
Form FDA 1572 (Statement of Investigator) Legal commitment by the PI to comply with FDA regulations (21 CFR 312), supervise the trial, report AEs, and list all sub-investigators and facilities. Sponsor TMF & ISF
Financial Disclosure Forms (FDF - 21 CFR 54) Discloses financial interests of the PI and Sub-Is to detect potential conflicts of interest (equity, significant payments, proprietary interests). Sponsor TMF (Site retains copies/record)
Curriculum Vitae (CV) & Medical Licenses Documents qualifications, education, experience, and active licensure of PI and Sub-Investigators to conduct the trial. Sponsor TMF & ISF
Medical / Lab / Technical Normal Ranges & Certifications Documents competence of facility/laboratory (e.g., CLIA, CAP, ISO accreditation) and establishes reference baselines for safety evaluations. Sponsor TMF & ISF
Instructions for Handling IP (Pharmacy Manual) Standard operating procedures for shipping, receipt, storage, preparation, reconstitution, dispensing, and disposal of IP. Sponsor TMF & ISF
Shipping Records & Certificate of Analysis (CoA) Confirms batch release, chemical purity/potency, shipment date, batch/lot numbers, and chain of custody for IP and trial supplies. Sponsor TMF & ISF
Decoding Procedures for Blinded Studies SOPs and mechanisms (e.g., interactive response technology / IVRS) permitting rapid unblinding in medical emergencies. Sponsor TMF & ISF
Master Randomization List Defines the allocation sequence of treatments; held under strict security to prevent premature unblinding. Sponsor TMF (Unblinded / Third-party only)
Pre-Trial / Site Selection Visit (SSV) Report Documents that site facilities, patient population, staff availability, and equipment were evaluated and determined suitable. Sponsor TMF
Site Initiation Visit (SIV) Report & Training Records Confirms that site personnel were thoroughly trained on protocol procedures, GCP, and study systems prior to site activation. Sponsor TMF & ISF +---------------------------------------------------------------------------------------------+
- | CRITICAL COMPLIANCE DISTINCTION |
- | |
- | Form FDA 1572 is a binding legal contract with the U.S. FDA required for studies conducted |
- | under a U.S. Investigational New Drug (IND) application. |
- | Key Commitments on the 1572 include: |
- | 1. Personally conduct or supervise the investigation. |
- | 2. Ensure all associates, colleagues, and employees assisting are informed of obligations. |
- | 3. Maintain adequate and accurate records (ALCOAC standards). |
- | 4. Report adverse experiences to the sponsor in accordance with 21 CFR 312.64. |
- | 5. Ensure the IRB complies with 21 CFR Part 56 and initial/continuing approvals are secured. |
- +---------------------------------------------------------------------------------------------+
3. Stage 2: During the Conduct of the Trial (Active Trial Documents)
During trial execution, essential documents capture the dynamic operations of the trial, ensuring that all modifications to the protocol, participant safety signals, drug accountability, and monitoring oversight are contemporaneously recorded.
- Essential Documents Generated During Trial Execution ACTIVE TRIAL ESSENTIAL DOCUMENTS
- +--------------------------+--------------------------+--------------------------+
- | REGULATORY & ETHICAL | SAFETY & MONITORING | SUBJECT & PRODUCT |
- +--------------------------+--------------------------+--------------------------+
- | * Protocol Amendments | * SAE Reports & CIOMS | * Signed Consent Forms |
- | * Revised ICF Approvals | * IND Safety Reports | * IP Accountability Logs |
- | * Continuing IRB Reviews | * IMV Monitoring Reports | * Screening/Enrollment |
- | * Updated CVs & Licenses | * CRA Follow-Up Letters | * Subject ID Code List |
- | * Delegation Log Updates | * Action Item Trackers | * Source Docs & eCRFs |
- +--------------------------+--------------------------+--------------------------+
Key Operational Documentation Requirements:
Protocol Amendments & Informed Consent Revisions:
Whenever a protocol amendment is issued that alters subject safety, trial design, or study procedures, it must receive written IRB/IEC approval and, where required, Regulatory Authority approval before implementation at the site (unless necessary to eliminate immediate hazards to participants under ICH E6(R3) Annex 1 2.5.4–2.5.5 / 21 CFR 312.66).
Revised Informed Consent Forms (ICFs) must be submitted to and approved by the IRB. Once approved, currently enrolled active participants must be re-consented using the updated version at their next scheduled visit or earlier if safety information dictates.
Staff Additions & Delegation of Authority Updates:
When new sub-investigators or coordinators join the study, their CV, professional medical license, and GCP/protocol training records must be collected and filed prior to their performing any study-related tasks.
The Delegation of Authority Log (DOAL) must be updated, signed, and dated by the Principal Investigator. For IND studies, if a new Sub-Investigator is added, Form FDA 1572 must be updated (or documented on an annual update per sponsor SOP).
Safety Notifications & Expedited Reports:
Sites must document all Adverse Events (AEs) in source records and report all Serious Adverse Events (SAEs) to the sponsor within 24 hours of awareness.
Sponsors must distribute IND Safety Reports / Suspected Unexpected Serious Adverse Reactions (SUSARs) to all participating investigators across all active sites. Investigators must file these in the ISF and submit them to their local IRB per the IRB's written reporting policies.
Investigational Product (IP) Accountability Records:
Continuous tracking of IP receipt, storage condition monitoring (daily temperature logs, minimum/maximum thermometers, continuous data loggers), dispensing to subjects, returns from subjects, and reconciliation.
Temperature excursions must be immediately quarantined and documented with sponsor technical assessments filed in the ISF and TMF.
Subject Identification Code List:
A confidential master key linking subject screening/enrollment ID numbers to subject full names, medical record numbers, and contact details.
MUST BE KEPT SECURELY AT THE SITE ONLY. Monitors and auditors may inspect it on-site for source data verification, but it is strictly forbidden from being copied, photographed, or uploaded into the sponsor TMF.
4. Stage 3: After Completion or Termination of the Trial (Post-Trial Documents)
Once the last subject completes their final follow-up visit (LPLV - Last Patient Last Visit) or if the trial is terminated prematurely, close-out activities commence to ensure all trial materials are reconciled, data is locked, and regulatory obligations are finalized.
Post-Trial Essential Documents Inventory
Post-Trial Document Key Contents & Purpose Archival Responsibility
Final IP Accountability & Destruction Records Full reconciliation of all IP received, dispensed, returned by subjects, and destroyed or returned to sponsor. Confirms no investigational drug remains unaccounted for. Sponsor TMF & ISF
Completed Subject Identification Code List Sealed and retained securely at the site. Allows identification of any participant if long-term medical follow-up or safety notification is required years later. ISF Only (Site Confidential)
Close-Out Monitoring Visit (COV) Report Comprehensive report by the CRA documenting reconciliation of all trial files, resolution of all outstanding data queries, return of study equipment, and notification of retention rules. Sponsor TMF (Letter to ISF)
Final Report to IRB/IEC & Regulatory Authorities Formal written notification to the ethics committee and regulatory authorities that the trial has concluded, summarizing participant enrollment, safety findings, and study outcome. Sponsor TMF & ISF
Clinical Study Report (CSR) Formal, comprehensive scientific report detailing the methodology, statistical analysis, safety, and efficacy results of the trial (ICH E3 guidelines). Sponsor TMF (Summary provided to PI)
Audit Certificate(s) (if applicable) Independent verification issued by quality assurance auditors confirming that audits were conducted in compliance with SOPs and GCP (does not include confidential audit findings). Sponsor TMF & ISF (if provided)
5. Real-World Case Scenario: The Protocol Amendment Cascade +------------------------------------------------------------------------------------------------+
- | SCENARIO: PROTOCOL AMENDMENT CASCADE |
- | |
- | Context: Protocol Phase III Oncology Trial - Protocol Amendment 03 is issued by the sponsor |
- | introducing a revised dosing schedule due to new pharmacodynamic data and updating the risk |
- | section regarding potential QT prolongation. |
- | |
- | Step 1: Sponsor submits Amendment 03 and revised ICF to Regulatory Authority & central IRB. |
- | Step 2: Site receives sponsor-approved amendment package; local IRB submits review. |
- | Step 3: Site receives documented IRB approval for Amendment 03 and revised ICF Version 4.0. |
- | Step 4: Site staff complete protocol-specific retraining on the new dosing schedule. |
- | Step 5: Retraining is documented on the Site Training Log BEFORE dosing any subject under Amd 3.|
- | Step 6: When Subject 104 arrives for Cycle 4 Visit, CRC administers ICF V4.0. Subject signs |
- | prior to undergoing ECG or receiving IP under the revised dosing schedule. |
- | Step 7: CRC files IRB approval letter, approved ICF, training record in ISF, and original ICF |
- | in subject's confidential research binder. |
- +------------------------------------------------------------------------------------------------+